SHANGHAI: China’s CanSino Biologics has entered the “test production phase” for its COVID-19 mRNA booster vaccine, the company said in a post on its social media account late on Thursday (Jan 5). The vaccine, known as CS-2034, targets new Omicron variants of the virus, which are responsible for the vast ma
This content was originally published here.
